Source: Dreamstime
Reading time: 2 minutes
On Wednesday, the U.S.-based holding company reported that it has so far administered 8 million COVID-19 vaccines.
The company’s shares went up 2.6% in premarket trading in response to the upbeat earnings results, as well as due to Walgreens Boots Alliance’s announcement that it will raise its 2021 profit forecast as it now expects mid-to-high single-digit growth.
Here are the main financial highlights from the company’s Q2 earnings report:
– 288.5 million prescriptions filled and earnings per share of $1.40
– Second-quarter revenue rose to $32.8 billion (analysts expected $35.53 billion)
– Net income amounted to $1.0 billion vs. $946 million a year earlier
While the pandemic has no doubt disrupted prescription volumes in the past months, the high demand for COVID-19 tests and vaccines has more than compensated for this, with Walgreens Boots Alliance stating as early as in Q1 that it expects to profit from its vaccination efforts in the second half of 2021.
Upcoming reports
See the full list of upcoming earnings reports for 5 – 9 April in the tables below.
Tuesday, 6th of April 2021
| Country of origin | Company name | Fiscal period |
|---|---|---|
| United States | Paychex Inc | Q3 2021 |
Thursday, 8th of April 2021
| Country of origin | Company name | Fiscal period |
|---|---|---|
| United States | Levi Strauss & Co | Q1 2021 |
| United States | Constellation Brands Inc | Q4 2021 |
| Germany | Gerresheimer AG | Q1 2021 |
***
Looking to trade on the global markets? Open a demo account in Delta Trading and test your strategies in a real market environment, without the risk of losing any real funds.
